Suppr超能文献

终末期肝病患者腹水的管理

Management of ascites in patients with end-stage liver disease.

作者信息

Saadeh Sherif, Davis Gary L

机构信息

Division of Hepatology, Baylor University Medical Center, Dallas, Texas, USA.

出版信息

Rev Gastroenterol Disord. 2004 Fall;4(4):175-85.

Abstract

Ascites is the most common complication in patients with decompensated cirrhosis. Approximately 50% of patients with compensated cirrhosis will develop ascites over a 10-year period. This occurrence is an important milestone in the natural history of end-stage liver disease because only 50% of patients survive 2 to 5 years (depending on the cause of cirrhosis) after its onset. Salt restriction and diuretics are the mainstays of therapy, and these measures are effective in approximately 90% of patients. Large-volume paracentesis or transjugular intrahepatic portosystemic shunt can be used in patients with refractory ascites as either a bridge to transplant or as palliation. Cirrhotic patients with ascites should be carefully monitored for the development of bacterial peritonitis, and those at greatest risk should receive antibiotic prophylaxis. When spontaneous bacterial peritonitis is suspected, prompt diagnostic paracentesis followed by broad-spectrum antibiotics and albumin infusion can be life saving. Orthotopic liver transplantation should be considered in all patients with decompensated liver disease with or without ascites.

摘要

腹水是失代偿期肝硬化患者最常见的并发症。约50%的代偿期肝硬化患者在10年内会出现腹水。这种情况是终末期肝病自然史中的一个重要里程碑,因为腹水出现后,只有50%的患者能存活2至5年(取决于肝硬化的病因)。限制钠盐摄入和使用利尿剂是主要的治疗方法,这些措施对约90%的患者有效。大量腹腔穿刺放液或经颈静脉肝内门体分流术可用于难治性腹水患者,作为移植的桥梁或姑息治疗手段。肝硬化腹水患者应密切监测是否发生细菌性腹膜炎,高危患者应接受抗生素预防性治疗。怀疑自发性细菌性腹膜炎时,及时进行诊断性腹腔穿刺,随后使用广谱抗生素并输注白蛋白可能挽救生命。所有失代偿期肝病患者,无论有无腹水,均应考虑原位肝移植。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验